Through our broad transactional experience, we understand the complex issues – including FDA and intellectual property issues – that these companies face in financings, licensings, acquisitions and strategic alliances. As such, the firm is regularly called upon to advise on the most significant transactions that take place within the sector.  In addition, our litigators regularly advise some of the industry's largest companies on major antitrust investigations and challenges, mass tort cases and consumer actions, patent litigation and other commercial disputes.

• We advised Charles River Laboratories on its approximately $1.6 billion proposed acquisition of WuXi PharmaTech, a leading ONG research and development outsourcing company with operations in China and the United States.
• We are advising CVS Caremark on its $1.25 billion acquisition of the Medicare Part D business of Universal American, a Rye Brook, New York-based Medicare Prescription Drug Plan sponsor.
• We advised the initial purchasers in connection with the $1 billion Rule 144A/Regulation S notes offering by Genzyme Corporation, a global biotechnology company.
• We advised Aetna on its $500 million acquisition of Medicity, a Salt Lake City, Utah-based health information exchange technology company.
• We advised Credit Suisse Securities (USA) as sole arranger and sole bookrunner in connection with a $500 million revolving loan credit facility and an incremental $500 million term loan credit facility for King Pharmaceuticals, an S&P 500 Index company headquartered in Bristol, Tennessee, that develops, manufactures and markets pharmaceutical therapies and technologies.
• We advised the joint book-running managers in connection with the $72 million initial public offering of common stock of Alimera Sciences, a biopharmaceutical company based in Georgia.